| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,640 | 3,560 | 19:00 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMAXIMA Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,85 | +1,18 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 20,060 | +1,01 % | Leerink Partners maintains Market Perform rating on Sarepta stock ahead of 2026 data | ||
| VIDAC PHARMA | 0,666 | +12,88 % | Achtung Anschnallen! 2026 wird zum Raketen-Start für Novo Nordisk, Evotec, Bayer und Vidac Pharma | Die Börse startet mit guter Laune ins neue Jahr 2026. Dass man nicht nur mit Tech-Aktien Geld verdienen kann, zeigte der Minen- und Rohstoffsektor, wo sich nahezu jeder Wert verdoppeln konnte und auch... ► Artikel lesen | |
| CYTODYN | 0,248 | +7,83 % | CytoDyn Inc. - 10-Q, Quarterly Report | ||
| ALDEYRA | 3,678 | +2,39 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| NOVOCURE | 12,780 | +0,08 % | Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference | Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank Leonard, Chief... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 11,330 | +2,44 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| REMEGEN CO LTD | 10,600 | +3,92 % | RemeGen Co., Ltd: 2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China | In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements... ► Artikel lesen | |
| MARAVAI LIFESCIENCES | 3,380 | +1,81 % | Maravai LifeSciences Reports Second Quarter 2025 Financial Results | Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue... ► Artikel lesen | |
| ABIONYX PHARMA | 3,645 | -0,68 % | ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract with TP ICAP (Europe) SA | Regulatory News:
Under the liquidity contract covering ABIONYX Pharma shares (FR0012616852 ABNX FP) entrusted to TP ICAP (Europe), the following assets were included in the liquidity account on... ► Artikel lesen | |
| TERNS PHARMACEUTICALS | 31,400 | -3,09 % | Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) | ||
| MEIRAGTX | 6,400 | +2,40 % | MeiraGTx inks $18.2M share purchase deal with Perceptive Advisors | ||
| ANEBULO PHARMACEUTICALS | 1,040 | +4,00 % | Anebulo Pharmaceuticals, Inc. Announces Its Intent to Commence a Self Tender Offer | AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic... ► Artikel lesen | |
| ANTENGENE | 0,476 | +0,85 % | Antengene Corporation Limited: Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA (Pembrolizumab) ± Chemotherapy | SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech... ► Artikel lesen |